Bayer Pharmaceuticals has signed a partnership with AI firm Iambic Therapeutics to use AI-powered platforms in small molecule drug discovery. The deal targets difficult-to-drug proteins that traditional methods have failed to reach, potentially expanding the pipeline of medicines across oncology, cardiology, neurology, and other specialty areas.
AI platforms Enchant and NeuralPLexer
Under the collaboration, Bayer gains access to two of Iambic's frontier AI models: Enchant and NeuralPLexer. Tom Miller, Co-Founder and CEO of Iambic, said the systems are "proving that better technology leads to better medicines." The platforms are designed to identify new drug candidates and shorten the time needed for lead optimisation, a phase that often stalls in traditional discovery workflows.
Juergen Eckhardt, Head of Business Development and Licensing at Bayer Pharmaceuticals, described the arrangement as an effort to "harness AI as a strategic driver of innovation." He added that the two companies aim to "translate cutting-edge technology into patient value" by integrating complementary capabilities across the R&D value chain.
Bayer manages about 40 active programmes, with small molecules making up 55% of its innovation portfolio. The partnership aligns with that balance, giving the company an external source of technology for the majority of its drug development work. For healthcare teams observing how AI for Healthcare is being applied in pharma, the collaboration shows a sourcing model rather than an internal build, which can influence partnership strategies elsewhere.
Decarbonisation milestone in Spain
Separately, Bayer's manufacturing site in northern Spain became the first plant in the region to fully decarbonise its operations. The project relied on a thermal storage system installed by utility Iberdrola, which converts renewable electricity into steam for industrial processes. Mario Ruiz-Tagle, CEO of Iberdrola Spain, said the installation is "the first major steam electrification project in Spain and one of the largest in the world."
Bayer has set a corporate target to reach net-zero greenhouse gas emissions by 2050 and plans to buy 100% of its electricity from renewable sources. The Spanish facility's achievement provides a technical proof point for industries that need high-temperature heat, offering a replicable model for other pharmaceutical and chemical sites. This application of AI for Science & Research is not directly tied to the Iambic deal, but it reflects a broader data-driven approach to operational efficiency across the company.
Why this matters for healthcare professionals
For those in drug development or clinical operations, the Bayer-Iambic agreement signals a concrete move toward AI-assisted small molecule design for hard-to-treat targets. It also highlights the growing practice of licensing external AI technologies rather than building them from scratch. On the sustainability side, the steam electrification in Spain demonstrates that industrial decarbonisation is technically feasible today, which matters for supply chain and ESG reporting teams. Both developments offer practical models that can shape planning in other health organisations.
Your membership also unlocks:
